Although autophagy enhances cell survival in nutrient-deprived cells by increasing adenosine triphosphate (ATP) production, it remains unclear if autophagy functions similarly in cells treated with cytotoxic chemotherapy agents. To address this issue, we measured both the ability of DNA damaging agents (Temozolomide, and Etoposide) to induce an autophagy-dependent production of ATP, and the effects of modulation of autophagy on drug-induced cell death. Both drugs induced an autophagyassociated increase in ATP production in multiple glioma cell lines. The drug-induced ATP surge could not be blocked by glucose starvation, but could be blocked by preincubation with the autophagy inhibitor 3-methyladenine (3-MA), an siRNA targeting beclin 1, or the mitochondrial inhibitor oligomycin. Inhibition of autophagy-induced ATP production increased nonapoptotic cell death associated with micronucleation, while restoration of the 3-MA-inhibited ATP surge by addition of pyruvate suppressed cell death. These results show that DNA damaging agents induce an autophagy-associated ATP surge that protects cells and may contribute to drug resistance. Autophagy is a process by which subcellular constituents are degraded in autophagosomes/autolysosomes in response to stress.
Autophagy is a process by which subcellular constituents are degraded in autophagosomes/autolysosomes in response to stress. 1 Whereas growth factors enhance the ability of metazoan cells to take up extracelluar nutrients and suppress autophagy, deprivation of either growth factors or extracellular nutrients leads to decreased nutrient uptake and derepression of autophagy. The catabolic autophagy process is believed to allow starving cells to support adenosine triphosphate (ATP) production and avoid cell death. 2, 3 The autophagic process is regulated by both class I and class III phosphatidylinositol 3-kinase (PI3K) pathways. 2, 4, 5 Mammalian target of Rapamycin (mTOR) functions downstream of the class-I PI3K/Akt, and is a key negative regulator of autophagy. In this role, mTOR serves as a metabolic sensor that coordinates crosstalk between nutrient availability and autophagy. 6, 7 In contrast, class III PI3K positively regulates autophagy. The formation of a preautophagosomal isolation membrane that encloses cytoplasmic cargo is positively regulated by phosphatidylinositol 3-phosphate, the products of class III PI3K phosphorylation. 4 It has also been suggested that the trafficking of autophagosomes is regulated by class III PI3Ks, 4, 5 an idea supported by the observation that 3-methyladenine (3-MA), which inhibits class III PI3K activity, also inhibits autophagosome formation and is widely used as an autophagy inhibitor. 5 It is also known that autophagy is induced in cancer cells derived from tissues such as breast, colon, prostate and brain in response to a variety of anticancer therapies. 3, 8 However, autophagy in response to these drugs can produce different outcomes, in some cases promoting cell adaptation and survival similar to what is seen in nutrient deprived cells, while in other cases, inducing programmed cell death type. The role of drug-induced autophagy in cell death or survival is therefore unresolved. 3, 8 Temozolomide (TMZ) is an alkylating agent which is widely used for treating primary and recurrent high-grade gliomas. 9 The cytotoxicity of TMZ is thought to result from the formation of O 6 -methylguanine in DNA, which mispairs with thymine during DNA replication triggering futile cycles of the mismatch repair system and subsequent DNA damage. 10 In glioma cells, the DNA damage induces a G2/M arrest, not apoptosis, and cell death occurs mainly by cell death associated with multimicronucleation, particularly in p53-deficient cells. 11, 12 In a previous study, it was shown that TMZ induces autophagy, and that pharmacological inhibition of autophagy could influence cellular oucome. 13 The exact means by which this occurred, however, and the potential role of autophagy -induced ATP production in the process, were not determined. In the present study, we investigated the relationship between autophagy, autophagy-associated ATP production, and cell death in response to TMZ and a second DNA damaging agent Etoposide.
Results
Effect of TMZ on malignant glioma cell lines. To begin to examine the antitumor effect of TMZ on malignant glioma cell lines, unsychronized U251 GBM cells were first treated with TMZ (100 mM for 3 h) and further incubated for 3-14 days in the absence of TMZ, after which cells were analyzed by FACS for DNA content. Consistent with previous reports, [11] [12] [13] cells accumulated with 4N DNA content at the G2-M boundary, with ratio of 4N/2N DNA content peaking 3 days after TMZ treatment and decreasing gradually to base levels by 10 days post-TMZ exposure (Figures 1a and b) .
TMZ was previously shown in p53-deficient glioma cells to induce cell death characterized by multimicronucleation in the absence of cytoplasmic shrinkage ('mitotic catastrophe'). 11, 12 Consistent with this observation, TMZ treated p53-deficient U251 cells stained with hematoxylin/ eosin exhibited multiple, micronucleated nuclei in the absence of cytoplasm shrinkage (arrows, Figure 1c) , with this form of cell death peaking 5-7 days post-TMZ exposure (2-4 days after the maximal G2 arrest; Figure 1b) . Consistent with previous reports, no apoptotic cells were detected microscopically or by cell cycle analysis (lack of cells with sub-G1 DNA content). [11] [12] [13] Finally, because recent investigations also demonstrated that radiation or chemotherapeutic agents including TMZ induce autophagy in malignant glioma cells, 13, 14 we measured conversion of microtubule-associated protein 1 lightchain 3 (MAP1-LC3) (LC3-I, 18 kDa), to a lipidized form (LC3-II, 16 kDa) in TMZ-treated cells as a measure of autophagy. As shown in Figure 1d , TMZ induced an accumulation of the LC3-II form of MAP1-LC3 as early as 3 days after TMZ exposure, similar to what was noted following a 1-day exposure of the cells to the known inducer of autophagy, rapamycin. To further verify that TMZ-induced autophagy was occurring, we indirectly measured the activity of mTOR, a key suppressor of autophagy, by looking at activation of its downstream targets S6K and 4E-BP1 in TMZ-treated cells.
As shown in Figure 1e , the phosphorylation of S6K was significantly downregulated 3 days following TMZ exposure, and 4E-BP1 was progressively hypophosphorylated (faster migrating band), consistent with downregulation of mTOR activity that accompanies autophagy. These results indicate that TMZ induces a G2 arrest followed by the induction of autophagy and a form of cell death preceded by multimicronucleation ('mitotic catastrophe').
TMZ-induced, autophagy-driven increases in ATP levels protect cells from the drug-induced cell death preceded by multinucleation. Because it has been reported that autophagy provides mitochondria with substrates to maintain oxidative phosphorylation in the absence of growth factors, 15 we examined whether TMZ-induced autophagy could have a similar ATP-producing effect. To assess the effects of TMZ on the levels of ATP, we used a luciferin-luciferase based ATP bioluminescence method that has been described previously. 16 ATP levels in U251 cells increased 3 days following TMZ exposure and peaked at over two times those of control cells 7 days after TMZ exposure, falling to control levels by 14 days after TMZ treatment (Figure 2a) . The time course of the ATP surge was consistent with that of autophagic processing of MAP1-LC3 to its lipidized form (LC3-II) (Figure 1d ), suggesting that this surge could be an autophagy-related process.
To clarify whether the TMZ-induced elevation of ATP levels was related to autophagy, we exposed cells to TMZ (0 or 100 mM, 3 h), then incubated the cells with 3-MA (a PI3K inhibitor widely used as a pharmacological inhibitor of autophagy), for 2 days beginning 3 days after TMZ exposure, and monitored effects on ATP production and autophagy. While 3-MA alone had no effect on ATP levels, the TMZinduced ATP surge (0 mM group; Figure 2b ) was inhibited by the addition of 3-MA in a dose dependent manner. 3-MA similarly did not alter the distribution between MAP1-LC3 forms (not shown), but inhibited the TMZ-induced conversion of MAP1-LC3 to a lipidized form (Figure 2c ). To determine if the autophagy-associated surge in ATP was related to cell outcome, we also monitored the percentage of cells undergoing multimicronucleation in cells treated similarly with TMZ, 3-MA or both. While a 2-4 day treatment with 3-MA up to 10 mM alone did not induce cell death (data not shown), the delayed 3-MA exposure that suppressed the TMZ-induced ATP surge also significantly increased the percentage of cells undergoing multimicronucleation in a dose-dependent manner (Figures 2d and e) .
Because 3-MA is a relatively nonspecific inhibitor of autophagy, especially when used at high concentrations, we repeated the studies in Figure 2 using an short hair pin RNA (shRNA) targeting beclin-1, a key component of autophagosome formation. As shown in the Western blot in Figure 3a , U251 cells stably expressing beclin shRNA exhibited significantly lower levels of beclin 1 relative to cells expressing a nontargeted shRNA (shNegCtrl). Cells expressing beclin shRNA also exhibited reduced conversion of MAP1-LC3 to . Because these data suggested that autophagy was a means by which cells protect themselves from multimicronucleation, and that the autophagy and micronucleation processes might be mutually exclusive, we also stably transfected U251 expressing negative control shRNA or shRNA targeting beclin 1 with constructs encoding GFP-LC3, after cells were incubated with TMZ (100 mM, 3 h). Five days later, cells were incubated with DAPI (to stain nuclei) and monitored by fluorescence microscopy for TMZ-induced GFP-LC3 clustering (a marker of autophagy) and multimicronucleation. As shown in Figure 3e , untreated cells expressing either the negative control or beclin-targeted shRNA exhibited a diffuse GFP staining consistent with a lack of autophagy (left panels), and no evidence of micronucleation (right panels). TMZ treatment of negative control cells or of cells expressing beclin shRNA led to the appearance of autophagic cells with a punctate GFP appearance and of cells with characteristics of micronucleation (more autophagic cells and fewer micronucleated cells in the negative control group) (Figure 3e , arrows). In no instance, however, did cells undergoing micronucleation exhibit punctate GFP staining. These results suggest that autophagy and micronucletion are, to the limits of our detection, mutually exclusive processes in TMZ-treated glioma cells. Finally, because multimicronucleation may not equate with cell death, we also directly measured the effects of beclin shRNA on the clonagenicity of U251 cells exposed to TMZ. As shown in Figure 4 , the same beclin shRNA that suppressed beclin levels, suppressed the TMZ-induced ATP surge, and enhanced TMZ-induced micronucleation also enhanced TMZ-induced cytotoxicty. These data as a whole suggest that TMZ induced autophagy-driven increases in ATP levels protect cells from the drug-induced cell death preceded multimicronucleation.
The TMZ-induced ATP surge is dependent on oxidative phosphorylation. To determine whether the TMZ-induced ATP elevation noted in GBM cells is dependent on catabolic metabolism (mitochondrial ATP production) as would be expected in response to autophagy, we blocked either anabolic metabolism (by inhibition of glycolysis) or catabolic metabolism (by addition of a mitochondrial inhibitor) in TMZtreated cells, and monitored ATP levels and cellular outcome. To do so, U251 cells were treated with TMZ (100 mM, 3 h) after which the cells were grown in drug-free media for 3 days. The TMZ-exposed cells were grown an additional 2 days in glucose-free media containing 2-deoxy-D-glucose (2DG, 10 mM) (to block glycolysis), or in glucosecontaining media supplemented with a mitochondrial F0, F1-ATPase inhibitor, oligomycin (1 mM) (to block the oxidative phosphorylation). Inhibition of glycolysis with 2DG did not block the TMZ-induced two-fold surge in ATP levels noted 5 or 7 days following TMZ exposure (Figure 5a ). 2DG incubation also neither enhanced the percentage of cells undergoing multimicronucleation (not shown) nor altered the extent of micronucleation in TMZ-treated cells (Figure 5b) , suggesting that the ATP surge that contributes to cell protection was not generated by glucose uptake and glycolysis. These results are consistent with the observation that TMZ-treated cells also downregulated GLUT-1, a major glucose transporter, in response to TMZ exposure ( Figure 5c ). However, when the oxidative phosphorylation in the mitochondria was blocked by exposure of TMZ-treated cells to a nontoxic, nonmicronucleation-inducing exposure of oligomycin (1 mM, not shown), the TMZ-induced ATP surge was abolished and the percentage of TMZ-treated cells that died a multimicronucleation-associated death was significantly increased (oligomycin groups, Figures 5a and b) . These results suggest that the TMZ-induced surge in ATP production is dependent not on glycolysis but on oxidative phosphorylation of substrates that can be provided by autophagy.
Because the TMZ-induced ATP surge that was generated by oxidative phosphorylation appeared to protect cells from cell death preceded by multimicronucleation, we tested whether providing exogenous substrates for oxidative phosphorylation to autophagy-deficient cells could enhance ATP levels and suppress cell death preceded by multimicronucleation. For these studies, U251 cells retrovirally infected with constructs encoding non-targeted shRNA or an shRNA targeting beclin 1 were permeabilized with filipin I (5 mM) (a sterol-binding agent that disrupts caveolae to permeabilize the cell 17 ), then incubated with pyruvate (0 or 25 mM) for 2 days beginning 3 days after TMZ exposure (0 or 100 mM, 3 h), after which ATP levels and the percentage of cells undergoing micronucleation were examined. As shown in Figure 5d , ATP levels were not significantly increased by permeabilization or incubation of shNeg control cells with pyruvate, although consistent with data shown in Figure 3c , TMZ exposure increased ATP levels approximately three-to six-fold in the absence or presence of pyruvate. In contrast, the TMZinduced ATP surge was suppressed in cells expressing shBeclin (compare the third bar in each group in Figure 5d ) but could be partially restored by providing pyruvate to the cells. As would be predicted, the genetic suppression of beclin levels also enhanced TMZ-induced multimicronucleation, an effect that could be reversed by provision of pyruvate (Figure 5e ). These results suggest that TMZ exposure induces autophagy and enhances ATP production, which in turn helps protect from cell death preceded by multimicronucleation.
To determine if our observations were unique to U251 cells, we repeated studies in two other p53-mutant glioma cells, U373 and SF188. Like TMZ-treated U251 cells, both TMZtreated U373 and SF188 cells exhibited G2-M arrest at 3-5 days post-TMZ exposure (Figure 6a ). The cells also exhibited an LC3-II accumulation at 4-5 days after TMZ treatment, which was inhibited by the delayed addition of 3-MA (Figure 6b ). We also observed downregulation of the phosphorylation of S6K and progressive hypophosphorylation of 4E-BP1 in both cell lines, consistent with downregulation of mTOR activity that accompanies autophagy ( Figure 6c ). As with U251 cells, analyses of ATP levels revealed a significant TMZ-induced elevation of ATP production. The delayed addition of 3-MA, while not altering ATP levels itself (not shown), did inhibit the TMZ-induced surge in ATP production (Figure 6d ), suggesting the ATP surge was associated with autophagy. Delayed 3-MA addition, while not altering micronucleation by itself (not shown) also resulted in a significant increase in TMZ-induced multimicronucleation in both cell lines (Figures 6d and e) . These results support the idea that TMZ-induced, autophagy-driven, cytoprotective increases in ATP levels are not unique to U251 cells but are also observed in other glioma cell lines such as U373 and SF188 cells.
Etoposide induces an autophagy-associated ATP elevation. Because it is known that autophagy is induced by multiple DNA damaging agents, 3, 8 we repeated studies in U251 cells using Etoposide to see whether the autophagyassociated cytoprotective ATP surge was unique to TMZ. As shown in Figure 7a , Etoposide (20 mM, 8 h) induced an Sphase and G2-arrest in U251 cells. Immunoblot analyses revealed the accumulation of LC3-II, which peaked 2 days after Etoposide exposure (Figure 7b ). In support of the Etoposide induction of autophagy, we also observed downregulation of the phosphorylation of S6K and progressive hypophosphorylatation of 4E-BP1 indicative of mTOR activity downregulation (Figure 7c ). The analyses of levels of ATP revealed an Etoposide-mediated elevation of ATP 3 days after the treatment (Figure 7d ) in a time course consistent with the autophagic process, suggesting that this ATP surge was an autophagy-related process. Delayed addition of 3-MA to filipin-permeabilized cells (which did not in itself alter ATP levels or micronucleation -not shown) also suppressed processing of MAP1-LC3 as well as the ATP elevation driven by Etoposide exposure (Figures 7e and d, respectively), and significantly increased the percentage of cells eliminated by cell death preceded by multimicronucleation (Figures 7d and f) . Furthermore, as shown in Figure 7d , co-incubation with pyruvate (0 or 25 mM) and 3-MA (24 h after starting the Etoposide-treatment), neither of which alone altered ATP levels or micronucleation (not shown) resulted in a statistically significant elevation of levels of ATP (Po0.01), which also partially reversed the enhanced cell death mediated by the addition of 3-MA. Similar results were obtained using SF188 cells (Figures 8a-e) . These results suggest that the autophagy-associated ATP surge that protects cells from drug-induced cell death is not unique to TMZ and can be reproduced by other DNA damaging agents such as Etoposide.
Discussion
The autophagic process has taken on increased importance following the recognition that it represents a novel form of cell death distinct from apoptosis and necrosis. 2, 3, [18] [19] [20] The role of drug-induced autophagy, however, is poorly understood, and given the protective role of autophagy in times of cellular starvation, it remains unclear whether the drug-induced autophagy noted following exposure of cells to agents such as TMZ is protective from, or contributory to, cell death. 3, 8 In this study, we show that autophagy induced by two distinct DNA damaging agents clearly protects several GBM cell lines from cell death preceded by multimicronucleation. Furthermore, this protection is associated with surges in ATP generated not by glycolysis but by oxidative phophorylation. The data presented therefore suggest that part of the cellular response to DNA damaging agents such as TMZ is the autophagic enhancement of catabolic metabolism and ATP levels which in turn provide a degree of cellular protection that may contribute to chemoresistance.
The present work firmly establishes a link between two distinct processes: drug-induced autophagy and suppression of cell death characterized by multimicronucleation. Previous work suggested that TMZ exposure induced autophagy in glioma cells and contributed to chemo-resistance, although this study did not examine ATP levels. 13 In the same study, however, it was also shown that inhibition of TMZ-induced autophagy by 3-MA modestly enhanced cell viability, rather than suppressed it as noted in the present study. In the present study we manipulated the autophagic process 3 days after a brief TMZ exposure (a time frame that coincides with the completion of the cell cycle arrest and the onset of autophagy), rather than continuously during TMZ exposure and cell cycle arrest as in the previous study. This allowed us to analyze the role of autophagy more precisely, and may explain some of the differences noted between the studies.
The present work also definitively shows that the autophagic increase in ATP production was dependent on oxidative phosphorylation following the induction of autophagy, and was also linked to suppression of cell death characterized by multimicronucleation. Previously, it has been reported that autophagy provides growth-factor deprived cells with oxidizable substrates to compensate for the loss of nutrient uptake, and allows cells to maintain ATP production via catabolic metabolism. 15 The results of the present study are consistent with those derived from growth factor-deprived cells, although the source of substrates for the oxidative phosphorylation in the present study can only be presumed to be autophagolysosome-processed catabolized cellular components. The induction of autophagy following TMZ or Etoposide exposure resulted in a surge of ATP production rather than a sustained elevation as noted following growth-factor deprivation, although the surge in ATP levels was larger than could be induced by supplying exogenous substrates for oxidative phosphorylation. Even relatively small increases in ATP levels, however, led to significant suppression of death characterized by multimicronucleation, suggesting that ATP levels are intimately linked to micronucleation sensitivity. Although the nature of this linkage is not clear, ATP plays a role in cellular maintenance, maintenance of DNA integrity, 21 and the reinitiation of the cell cycle. 22 The autophagyassociated surge in ATP may therefore allow cells to maintain normal function in the face of extensive DNA damage. In this sense, autophagy may serve a cooperative role with cell cycle checkpoints in allowing the cell time to deal with DNA damage. Given that TMZ activates signaling pathways that control the G2 checkpoint (including Akt-mTOR 23 ) as well as the autophagic process, the linkage between DNA damage and the G2 checkpoint may also extend to autophagy. These ideas remain to be examined.
The present work also suggests that drug-induced autophagy and its resultant cytoprotective surge in ATP levels may be a generalized mechanism of resistance to chemotherapeutic agents. The present study shows that two unrelated agents both induce autophagy, a surge in ATP, and protection from one form of cell death. Both TMZ and Etoposide, however, are DNA damaging compounds that induced cell cycle arrest, and in this regard autophagy may be a more specific response to compounds that generate potentially lethal DNA damage. Consistent with this idea, the ability of TMZ to induce autophagy is not related to generalized cell stress, but rather to the generation of DNA lesions (O 6 -methylguanine) that lead to DNA damage in the form of DNA single, and double strand breaks (Kanzawa et al.
14 and unpublished data). The importance of autophagy may also however vary by the genetic background of the cells examined. The present studies were limited to p53-mutant glioma cells because in these cells the predominant form of TMZ-induced cell death is multinucleation rather than apoptosis or senescence. 11, 12 While most GBM are similarly defective in the p53 pathway and presumably influenced by autophagy, tumors of other genetic backgrounds may be less influenced by the autophagic process. These issues remain to be defined.
The present study clearly shows that the autophagic process induced by TMZ and Etoposide can contribute to resistance to these agents, suggesting that differences in the ability of cells to activate this process may contribute to their sensitivity to these drugs. Modulation of the autophagic pathway may be a novel way of modifying resistance to TMZ, Etoposide, and perhaps an even broader range of chemotherapeutic agents, and as such warrants further examination. Drug treatment. For studies examining the effect of TMZ on U251 and U373 cells, unsynchronized, subconfluent cells were exposed to TMZ (0 or 100 mM) for 3 h, after which the cells were washed, placed in TMZ-free medium, and harvested at appropriate time points. For experiments in SF188 cells, unsynchronized, subconfluent cells were pretreated with 10 mM BG for 2 h to deplete MGMT, followed by incubation with 100 mM TMZ for 3 h in the presence of BG (10 mM), after which the cells were washed, placed in BG (10mM) supplemented, TMZ-free media, and grown until harvest. For studies examining the effect of Etoposide in U251 and SF188 cells, the cells were exposed to 20 mM Etoposide for 8 h, after which the cells were washed, placed in Etoposide-free medium, and harvested at time points of interest. For all experiments, the cells were plated at least 24 h before the drug treatment, and final DMSO concentration did not exceed 0.1% (v/v).
3-MA was dissolved directly into culture media, aliquoted and stored at À201 until used. In the studies using 3-MA, drug-free media was exchanged for media containing 0-10 mM 3-MA beginning 2 days prior to harvest for TMZ-treated cells, and 1 day or 2 days prior to harvest for Etoposide treated cells. 2-DG and oligomycin were dissolved in water and 100% ethanol respectively, and in studies using these agents, drug-free media was replaced with media containing 1 mM oligomycin or with glucose-free media containing 10 mM 2-DG beginning 2 days prior to harvest. Sodium pyruvate and filipin1 were dissolved in water and 100% ethanol, respectively, and in studies using these agents, sodium pyruvate and filipin1 were added (25 mM and 5 mg/ml respectively) to drug-free media beginning 2 days prior to harvest.
Cell cycle studies. Cell cycle analyses were done as previously described. 11 Briefly, at each time point after the treatment, the cells attached to the culture dish were trypsinized and collected. These cells were washed in PBS, fixed in 70% (v/v) ethanol, and stored at À201. The cells were washed once with PBS followed by incubation in PBS containing 20 mg/ml propidium iodide (Sigma Chemical Co.) and 100 mg/ml RNaseA (Sigma Chemical Co.) for 1 h at room temperature in the dark. Stained nuclei were then analyzed using a Becton Dickinson FACScan (San Jose, CA) with 20 000 events/determination. ModFitLT software (Verity Software House, Inc., Topsham, ME) was used to assess cell cycle distribution.
Immunoblot analyses. Preparation of protein samples and Western blot were performed as described previously 11 with minor modifications. Whole-cell lysate (0.5-5 mg) were electrophoresed and electroblotted onto an Immobilon-P membrane (Millipore, Bedford, MA). The membrane was blocked in 5% skim milk (Bio-Rad Laboratories)/TBST or 5% BSA (Sigma)/TBST for an hour and probed with antibodies to phosphorylated S6K (Thr389), 4E-BP1 (Cell Signaling Technology, Beverly, MA), GLUT-1 (Chemicon, Temecula, CA), Beclin-1 (BD Pharmingen, Beverly, MA) or a-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA) at 41C overnight. Bound antibody was detected with the appropriate horseradish peroxidase-labeled secondary antibodies (Cell Signaling Technology, Beverly, MA and Santa Cruz Biotechnology) using enhanced chemiluminescence Western blotting detection reagents (Pierce, Rockford, IL).
To assess the autophagic processing of MAP1-LC3, the cells were collected separately from the samples above by a modified method as described previously. 24 Briefly, 3 h prior to collection of the samples, E64d (10 mg/ml) and pepstatin A (10 mg/ml) were added. After 3 h, the cells were washed with PBS, trypsinized, split into equal halves, and centrifuged to obtain cellular pellets. One half was used to determine protein concentration using Protein Assay reagent (Bio-Rad Laboratories, Hercules, CA) while the other half was lysed directly using LDS sample buffer to achieve a final concentration of 1ug/ul. Protein aliquots (10 mg) were then subjected to the immunoblot analysis and probed with antibodies to MAP1-LC3 (H-50) or alpha-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA) at 41C overnight with detection as described above.
Measurement of ATP content. ATP levels were measured as described previously. 16 Briefly, control and drug-treated cells were trypsinized and collected, counted in triplicate using a Coulter Z2 Particle Count and Size Analyzer (Coulter Corporation, Miami, FL), after which cells (2500-10 000 cells/50 ml) were placed in a 96-well plate, eight wells per sample. ATP levels were measured by the luciferinluciferase method using an ATP Bioluminescence Assay Kit (CellTiter-Glo Luminescent Cell viability assay, Promega, USA). A standard curve was generated from known concentrations of ATP for each experiment to reassure the reproducibility of each experiment. Each experiment was carried out at least in triplicate.
Measurement of multimicronucleated cells. For measurement of multimicronucleated cells, cells were seeded on chamber slides (Lab-Tec I chamber slide system, Nalge Nunc, Rochester, NY) at least 24 h before exposure to TMZ (100 mM, 3 h) or Etoposide (20 mM, 8 h). Control cells and cells at each time point after the indicated treatment were fixed with 4% paraformaldehyde/0.25% Triton X-100/PBS for 10 min at room temperature, rinsed with PBS, then stained with hematoxylin/eosin. The cells that were large (absent of cytoplasmic shrinkage) and contained separate micronuclei with evenly stained chromatin (absence of chromatin condensation) were defined as multinucleated cells as reported previously. 19, 25, 26 The percentage of multimicronucleated cells was determined after scoring more than 100 nuclei for each experiment. Each experiment was repeated at least three times.
shRNA constructs. pSilencer negative control and pSilencer (Ambion, Austin, TX) were a gift from Dr. Yong-Won Kwon (University of California San Francisco). The sequence of the shRNA targeting Beclin-1 was that described in a previous publication, 27 and the shRNA cassette was subcloned into the BamHI-HindIII site. U251 cells were transfected by Nucleofector transfection (Amaxa, Gaithersburg, MD) using program T-20. At 48 h post-transfection, the cells were selected by supplementing DMEM with puromycin (400 ng/ml) for 7 days to obtain a pooled population of U251 cells stably expressing the shRNA construct.
